Trimerbody Pharma

Leadartis, formerly known as Trimerbody Pharma, is a Spanish biotechnology company focused on the development of next-generation multispecific antibodies for cancer immunotherapy. The company's proprietary Trimerbody platform enables the design of multivalent and multispecific molecules that mimic the natural architecture of the TNF ligand family, providing enhanced potency and selectivity. Their pipeline includes several bispecific and trispecific candidates targeting immune checkpoints and tumor-associated antigens to overcome resistance in solid tumors. Leadartis operates out of Madrid and collaborates with leading clinical institutions to advance its novel antibody formats toward clinical trials.